HEPA — Hepion Pharmaceuticals, Inc.

—
OTC · Health Care · Pharmaceuticals · CIK 1583771 ·
Last close
$0.12
Market Cap
$10.38M
52W High
$0.22
52W Low
$0.03
ADV30
32,000
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -1,211,491 -1,248,237 1,927,442 1,628,625 648,923
Mar 2026 0 — -798,509 -810,791 2,705,503 2,602,580 848,747
Dec 2025 0 — -609,683 -656,885 3,069,952 1,828,062 402,405
Sep 2025 0 — -527,902 -472,506 3,740,240 2,321,078 415,808

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-1,594,109
Investing CF
$0
Financing CF
$298,339
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.28
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-248,156,684
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-7,650,237
Pretax Income TTM
$-3,188,419
Interest Exp TTM
$26,940
Analysts
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -3,760,945 -8,277,850 3,069,952 402,405 2,667,547 -3,271,520
Dec 2024 0 -19,346,578 -13,192,420 1,613,737 3,477,075 -1,863,338 -18,216,303
Dec 2023 0 -45,257,954 -48,926,042 18,094,397 10,813,590 7,280,807 -40,888,878
Dec 2022 0 -43,617,802 -42,200,049 60,244,452 10,388,515 49,855,937 -34,961,171
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-3,188,419
OpCashFlow TTM
—
Assets (Latest)
$1,927,442
Forward EPS
$-11.43

Peers — same industry

TickerNameMarket CapLastDaily %
QNTM Quantum Biopharma Ltd. $10.22M $1.59 —
HIND Vyome Holdings, Inc $10.84M $1.54 —
RADX Radiopharm Theranostics Ltd $9.70M $0.67 —
BIVI BIOVIE INC. $9.61M $1.00 —
LSTA LISATA THERAPEUTICS, INC. $11.24M $1.04 —

News headlines (Yahoo Finance, 1h cache)

Hepion Pharmaceuticals Receives FDA Feedback Supporting a Path to Demonstrating Prophylactic Protection for GV104 Against Fentanyl-Induced Cardiac Arrest
2026-10-26 12:01 · Yahoo
Hepion Pharmaceuticals Receives Positive FDA Response on GV104 in Gambling Disorder, a Condition With No Approved Medication
2026-10-19 12:01 · Yahoo
Hepion Pharmaceuticals Completes Acquisition of Gravitas Life Sciences and Provides Corporate Update
2026-10-14 12:01 · Yahoo
Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma
2026-03-03 12:35 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.